What's in Fundación Santa Fe de Bogota's pipeline?

Fundación Santa Fe de Bogota has 6 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 3 in Phase 1.

Which companies overlap with Fundación Santa Fe de Bogota's portfolio?

Top competitors by shared drug class: Algemeen Ziekenhuis Maria Middelares.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/fundaci-n-santa-fe-de-bogota.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Fundación Santa Fe de Bogota — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fundación Santa Fe de Bogota pipeline: 2 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 1 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Lactate Ringer	Lactate Ringer	marketed
Plasma-lyte	Plasma-lyte	marketed	Crystalloid intravenous fluid / Electrolyte replacement solution		Critical Care / Fluid and Electrolyte Management

Therapeutic area mix

Critical Care / Fluid and Electrolyte Management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Algemeen Ziekenhuis Maria Middelares · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fundación Santa Fe de Bogota:

Cite this brief

Drug Landscape (2026). Fundación Santa Fe de Bogota — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fundaci-n-santa-fe-de-bogota. Accessed 2026-05-17.